Epidermal Growth Factor Receptor as a Target for Chemotherapy
References (57)
- et al.
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
Lancet
(2000) EGF receptor
Int J Biochem Cell Biol
(1999)- et al.
Epidermal growth factorrelated peptides and their receptors in human malignancies
Crit Rev Oncol Hematol
(1995) - et al.
Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation
Cancer Treat Rev
(2004) - et al.
Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody
Int J Radiat Oncol Biol Phys
(2004) - et al.
Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy
Crit Rev Oncol Hematol
(2001) - et al.
Cancer statistics, 2005
CA Cancer J Clin
(2005) - et al.
Capecitabine: the new generation of fluoropyrimidines in colorectal cancer
Exp Rev Anticancer Ther
(2004) - et al.
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
J Clin Oncol
(2000) - et al.
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
N Engl J Med
(2004)
Why the epidermal growth factor receptor? The rationale for cancer therapy
Oncologist
(2002)
Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy
Cancer
(2002)
The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities
Eur J Cancer
(2001)
The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer
Cancer
(1993)
Increased epidermal growth factor receptor in multidrug-resistant human neuroblastoma cells
J Cell Biochem
(1988)
Targeting the epidermal growth factor receptor
Br J Cancer
(2004)
The EGF receptor family as targets for cancer therapy
Oncogene
(2000)
Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model
Clin Cancer Res
(1995)
ERBITUX® (Cetuximab) [package insert]
(June 2004)
Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR)
Proc Am Soc Clin Oncol
(2001)
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
J Clin Oncol
(2004)
Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin
Proc Am Soc Clin Oncol
(2004)
An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing epidermal growth factor receptor (EGFR): Preliminary results
Proc Am Soc Clin Oncol
(2004)
Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR)
Proc Am Soc Clin Oncol
(2002)
Pharmacokinetic (PK) evaluation of cetuximab in combination with weekly irinotecan (CPT-11) and 24h infusional 5-FU/folinic acid (FA) as first line treatment in patients (pts) with epidermal growth factor receptor (EGFR)-positive metastatic colorectal cancer (MCRC)
Proc Am Soc Clin Oncol
(2003)
Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal CA
Proc Am Soc Clin Oncol
(2004)
Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225
Br J Dermatol
(2001)
The humanized monoclonal anti-EGFR antibody EMD72000 potently inhibits the growth of EGFR-expressing human tumor xenografts insensitive to chemotherapeutic drugs
Proc Am Assoc Cancer Res
(2003)
Cited by (0)
Electronic forwarding or copying is a violation of US and International Copyright Laws.
Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Cancer Information Group, ISSN #1533-0028, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA 978-750-8400.
Copyright © 2005 Elsevier Inc. All rights reserved.